MA-EVERBRIDGE,-INC.
23.3.2020 13:02:12 CET | Business Wire | Press release
Everbridge , Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM ), today announced that the company has launched COVID-19 Shield , a new set of Coronavirus Protection Solutions designed to protect the safety of employees and customers, maintain business operations, safeguard supply chains , and reduce costs and liabilities stemming from the impact of the global coronavirus pandemic . Drawing upon 18 years of crisis management experience, Everbridge’s purpose-built packages mitigate the impact of coronavirus by leveraging the company’s industry-leading CEM platform, used by over 5,000 enterprises globally, to help organizations identify their risks, safeguard their workforce, and manage disruptions to their operations and supply chain. Due to the swift spread of the outbreak, Everbridge offers a Rapid Deployment package for governments , businesses, and healthcare entities to implement the COVID-19 Shield solutions in under 48 hours.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200323005134/en/
COVID-19 Shield offers three new out-of-the-box solutions to help organizations. The individual offerings include Know Your Risks through COVID-19 alerts correlated to an organization’s locations. This solution offers pandemic Situation Reports developed from the world’s largest vetted database of risk data, drawn from machine learning analysis of over 22,000 data sources from 175+ countries and validated by a 24/7 team of analysts monitoring local verified sources. The real-time intelligence includes case statistics, travel advisories, closures and supply chain impacts, all automatically correlated to a business’ affected people and assets.
Secondly, COVID-19 Shield offers Protect Your People to manage critical response plans and automate communications with impacted people, responders, leadership and other stakeholders. Protect Your People correlates a specialized Everbridge-developed threat feed on incidences of the coronavirus with the previously visited, last known and expected location of people in order to help businesses understand the risks to their organization and take appropriate actions. It includes out-of-the box coronavirus-tailored messaging templates for health advisories, travel bans, work-at-home directives, and regular wellness checks. Organizations can also establish high-risk Incident Zones and send instructions when anyone enters these areas.
Thirdly, COVID-19 Shield helps Protect Your Operations and Supply Chains by automatically correlating alerts to physical assets including offices and facilities, production plants, suppliers and supply chain routes, in addition to people. Protect Your Operations pinpoints potential impacts to your assets and production resources, as well as to your suppliers and distribution routes, automates initiating standard operating procedures to quickly resolve issues, and generates real-time status reports on key remediation and recovery tasks. Additionally, the offering reduces liability through full audit trails and after-action reporting. By gaining an organization more time and a more complete picture from which to act, Protect Your Operations enables management teams to be more proactive in mitigating the consequences of the coronavirus.
The COVID-19 Shield packages also provide access to the Everbridge Data Sharing Private Network, which enables customers to share information publicly or privately. A business, for example, can share information with local government agencies and healthcare facilities to gain more local situation intelligence and to better coordinate response activities.
“Staying ahead of the coronavirus continues to be a major challenge for governments, businesses and healthcare systems across the globe,” said Claudia Dent, SVP of Product Marketing at Everbridge. “Everbridge works with thousands of organizations to help them protect their people and their operations. In one week alone, our customers sent more than 30 million coronavirus communications using our platform, a testament to the need for accurate and real-time information in a quickly evolving situation.”
“Organizations around the world have found a continuous need for relevant information and insights that are actionable and can be quickly deployed to protect their people, operations and supply chains from the impacts of coronavirus,” said Rebecca Scorzato, Partner at leading specialist risk consultancy, Control Risks . “As the CEM leader for almost 20 years, Everbridge is uniquely positioned to meet this need and to provide highly relevant information to help understand and mitigate the impacts of this global outbreak.”
In recent weeks, Everbridge has launched a series of actions to address the coronavirus, including providing daily updates on its Coronavirus Preparedness Hub , producing preparedness kits from its experience working with customers on previous widespread medical emergencies, hosting webinars with pandemic preparedness experts, and working with customers to make sure their deployments are ready for the increased activity related to the virus.
Everbridge leveraged its deep, global experience with managing critical events to assemble the coronavirus-related resources. The CEM platform reaches over 550 million people across the world while serving leading F500 companies and well as serving cities , states , and entire countries . Everbridge has been selected by eight countries , several states in India, and multiple states in the United States to protect populations.
About Everbridge
Everbridge , Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order to keep people safe and businesses running. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,000 global customers rely on the company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. The company’s platform sent over 3.5 billion messages in 2019 and offers the ability to reach over 550 million people in more than 200 countries and territories, including the entire mobile populations on a country-wide scale in Australia, Greece, Iceland, the Netherlands, Peru, Singapore, Sweden, and a number of the largest states in India. The company’s critical communications and enterprise safety applications include Mass Notification, Incident Management, Safety Connection™, IT Alerting, Visual Command Center® , Public Warning, Crisis Management, Community Engagement™ and Secure Messaging. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 7 of the 10 largest global auto makers, all 4 of the largest global accounting firms, 9 of the 10 largest U.S.-based health care providers, and 6 of the 10 largest technology companies in the world. Everbridge is based in Boston and Los Angeles with additional offices in Lansing, San Francisco, Abu Dhabi, Beijing, Bangalore, Kolkata, London, Munich, New York, Oslo, Singapore, Stockholm and Tilburg. For more information, visit www.everbridge.com , read the company blog , and follow on LinkedIn , Twitter , and Facebook .
Cautionary Language Concerning Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200323005134/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
